Adiponectin Polymorphisms, Insulin Resistance, and Pharmacokinetics in Obesity

Completed · Phase 1

Conditions studied: Obesity

In brief

The primary objective of this study is to determine the influence of insulin resistance on drug metabolism and response in obese subjects. The investigators hypothesize that expression of adiponectin (a hormone secreted by fat tissue), and specific variants in the adiponectin gene can predict the insulin resistance and drug response among obese subjects.

Key facts

Study ID

NCT01593397

Run by

Stanford University

People needed

100

Starts

2011-11-01

Expected to finish

2017-09-01

Last updated by the study team

2017-12-29

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Inclusion criteria include patients of adult age
• American Society of Anesthesiologists Class I, II, or III, and undergoing elective surgical procedures requiring general anesthesia
• Body mass index greater than 35

You may not qualify if…

• Patients with evidence of hepatic, renal, or cardiovascular dysfunction
• History of difficult tracheal intubation, or adverse reaction to anesthesia shall be excluded from the study
• Patients taking prescribed or over-the-counter anxiolytics, narcotics, or sleeping aids, will also be excluded

Where it is running

• Stanford University School of Medicine, Department of Anesthesia — Stanford, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.